Heart failure (HF) is a growing global health concern, affecting more than 64 million people worldwide. It develops when the ...

Researchers at Tohoku University have discovered that an oral drug called MA-5 can improve both heart and muscle problems in ...

Ifetroban improved heart function and reduced cardiac damage biomarkers in people with DMD in a Phase 2 clinical trial.

Researchers at Tohoku University have discovered that an oral drug called MA-5 can improve both heart and muscle problems in ...

Researchers at UT Arlington have discovered a key enzyme, IDO1, that when blocked, helps immune cells regain their ability to properly process cholesterol—something that breaks down during ...

Heart attack survival odds have dramatically improved over the past 5 decades, but more people are dying from chronic cardiac ...

By shutting this “off switch,” immune cells called macrophages regain their ability to soak up cholesterol, potentially ...

InterShunt Technologies announced today that it began an early feasibility study of its device for reducing heart failure symptoms.

Patients were screened from both a single cardiologist practice and a specialty heart failure (HF) clinic and were included ... making both interventions viable and better than treatment as usual. Our ...

“Thankfully, we’ve made progress in better identifying patients and administering treatment quickly, so they’re living longer, but they then develop the secondary consequence of progressive heart ...

Regardless of chronic obstructive pulmonary disease status, finerenone mitigates clinical events and symptoms in patients with HFmrEF or HFpEF.

Advances in heart failure treatment have reduced hospitalizations by up to 30% and extended lives by years. Learn about prevention strategies and research developments.